Lilly plans Elanco IPO, posts quarterly profit above estimates

By Tamara Mathias and Michael Erman (Reuters) - Eli Lilly and Co said on Tuesday it would take its Elanco animal health business public and posted a better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog. Lilly also said it would not increase its drug prices through the end of the year, following similar moves by Pfizer Inc, Merck & Co Inc and Novartis AG, as the Trump Administration pushes to cut costs for patients. Shares of the company rose as much as 2.6 percent to a near three-year high of $91.20.

Reuters July 25, 2018 00:05:19 IST
Lilly plans Elanco IPO, posts quarterly profit above estimates

Lilly plans Elanco IPO posts quarterly profit above estimates

By Tamara Mathias and Michael Erman

(Reuters) - Eli Lilly and Co said on Tuesday it would take its Elanco animal health business public and posted a better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

Lilly also said it would not increase its drug prices through the end of the year, following similar moves by Pfizer Inc, Merck & Co Inc and Novartis AG, as the Trump Administration pushes to cut costs for patients.

Shares of the company rose as much as 2.6 percent to a near three-year high of $91.20.

"We remain focused on driving revenue growth through volume, not price," Chief Executive David Ricks said on a conference call.

But the move may not be seen by some as having a wider impact.

"Looks to me like Lilly's statement means nothing. They haven't raised prices during the summer or fall months in the past several years," said Michael Rea, CEO of Rx Savings Solutions, whose software helps health plans and others save money on prescription drugs.

The Indiana-based drugmaker raised its full-year profit forecast to $5.40 to $5.50 per share from $5.10 to $5.20 per share, and said the forecast did not assume U.S. price increases for the rest of the year.

ANIMAL HEALTH IPO

Lilly's decision to take Elanco public marks the end of a nine-month review that weighed options for the unit, which could have a valuation of several billion dollars following the IPO.

Lilly plans to offer less than 20 percent of Elanco, which brought in sales of $792.1 million in the quarter, and debut it on the public market in the second half of 2018.

The market value of top animal-health company Zoetis Inc has nearly tripled since Pfizer listed it about five years ago, an example that analysts have noted in light of Lilly's decision for Elanco.

"Given Zoetis' high valuation, (the Elanco IPO) is a smart move," BMO Capital Markets analyst Alex Arfaei said. "We estimate that Elanco is worth about $13 billion."

Excluding items, Lilly earned $1.50 per share in the second quarter, ahead of analysts' average estimate of $1.30 per share, according to Thomson Reuters I/B/E/S.

Lilly's drug Trulicity had sales of $779.8 million, above analysts' estimates of $712.67 million, and overtaking Humalog as its best-selling drug. Humalog recorded revenue of $769.8 million, beating expectations of $683.67 million.

The company also announced a $8 billion share buyback program.

(Reporting by Tamara Mathias in Bengaluru and Michael Erman in New York; Editing by Supriya Kurane and Sweta Singh)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Oil rises 2% as OPEC complies with production cuts
Business

Oil rises 2% as OPEC complies with production cuts

By Jessica Resnick-Ault NEW YORK (Reuters) - Oil prices strengthened on Wednesday, as OPEC and its allies were seen complying with a pact to cut oil supply in September, even as concerns loomed that recovery in fuel demand will be stalled by soaring global coronavirus cases. Early in the day crude was boosted by a bullish stock market. Even as equities whipsawed on pandemic worries, oil stayed higher, buoyed by expectations that OPEC could staunch a supply glut

Tesla's back-to-back price cuts bring sticker on U.S. Model S below $70,000
Business

Tesla's back-to-back price cuts bring sticker on U.S. Model S below $70,000

By Tina Bellon and C Nivedita (Reuters) - Tesla Inc will further cut the price of its Model S "Long Range" sedan in the United States to $69,420, the electric carmaker's chief executive, Elon Musk, announced in a tweet https://bit.ly/2H0JCP0 on Wednesday. The anticipated drop marks the second time this week Tesla has cut the price for the high-end sedan, following a 4% cut of the Model S's price in the United States on Tuesday to $71,990.

Trump cites teenaged son's bout with coronavirus in calling for schools to reopen
World

Trump cites teenaged son's bout with coronavirus in calling for schools to reopen

By Jeff Mason DES MOINES, Iowa (Reuters) - Under siege over his handling of the novel coronavirus pandemic, President Donald Trump on Wednesday cited what he said was his son's mild bout of the virus as a reason why American schools should reopen as soon as possible. Trump made the comment about his son, Barron, as the president swept into Iowa on a mission to shore up support in battleground states that he won in 2016 but is in danger of losing to Democrat Joe Biden barely three weeks before the election. First lady Melania Trump announced in a statement earlier in the day that the virus that struck both her and her husband had also infected their 14-year-old son